Rx Price Controls Likely Unless Manufacturers Help Curb Costs, Vt. Gov. Says
Executive Summary
Pharmaceutical price controls may be imminent if manufacturers do not cooperate with government efforts to curb prescription drug costs, Vermont Gov. Howard Dean (D), MD, cautioned March 28.
You may also be interested in...
South Carolina SilverCard Rx Purchasing Program Enrolls 33,000 Seniors
Approximately 33,000 South Carolina seniors earning less than 175% of the federal poverty level have enrolled in the state's SilverCard prescription drug purchasing program.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials